Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 02, 2016 09:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
January 22, 2016 09:01 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces Abstract Selected for Oral Presentation at the 2016 Keystone Symposia

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
December 06, 2015 10:25 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Phase I Data for CB-839 in Patients With Hematological Malignancies at the 57th American Society of Hematology Annual Meeting

First results of CB-839 dosed in combination therapy Promising clinical activity with early signs of biologic activity, tolerability, and durability SOUTH SAN FRANCISCO, Calif., Dec. 06, 2015 ...
November 16, 2015 16:06 ET | Source: Calithera Biosciences, Inc.

Calithera Presents Preclinical Study Findings for CB-839 at the 2015 Novel Cancer Therapeutics Summit

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
November 09, 2015 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Third Quarter 2015 Financial Results and Recent Highlights

-Single Agent Solid Tumor Clinical Benefit Seen With Tumor Metabolism Inhibitor CB-839 -Continued Signs of Activity, Tolerability, and Durability -First Preclinical Data Presented For...
November 08, 2015 12:15 ET | Source: Calithera Biosciences, Inc.

Calithera to Present New Phase 1 Solid Tumor Dose Expansion Data of CB-839 at the 2015 AACR-NCI-EORTC International Conference

- Single Agent Solid Tumor Clinical Benefit Seen With Tumor Metabolism Inhibitor CB-839 - Continued Signs of Activity, Tolerability, and Durability SOUTH SAN FRANCISCO, Calif., Nov. 08,...
November 06, 2015 09:00 ET | Source: Calithera Biosciences, Inc.

Calithera Presents Preclinical Study Findings for CB-1158 at the 2015 AACR-NCI-EORTC International Conference

Potential to Combine With Anti-CTLA-4, Anti-PD-1 and Other Immuno-Oncology TherapiesIND Filing Remains on Track for 1H2016 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2015 (GLOBE NEWSWIRE) -- ...
November 05, 2015 09:06 ET | Source: Calithera Biosciences, Inc.

Calithera Announces Multiple Abstracts Selected for Presentation at the 57th American Society of Hematology Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), announced today that four abstracts highlighting the potential of CB-839, the Company’s...
October 30, 2015 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Third Quarter 2015 Financial Results on Monday, November 9, 2015

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
October 26, 2015 17:08 ET | Source: Calithera Biosciences, Inc.

Calithera Announces Multiple Abstracts Selected for Presentation at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...